Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hepatitis B antigen most commonly refers to the hepatitis B surface antigen (HBsAg), a protein present on the outer envelope of the hepatitis B virus (HBV). HBsAg is used as a marker in blood tests to detect acute or chronic HBV infection. Its presence in blood indicates that a person is currently infected with HBV and can transmit the virus to others. The detection of this antigen is one of the earliest signs of infection and forms part of standard diagnostic panels for hepatitis B. In addition to its diagnostic role, purified recombinant HBsAg is also used as the active component in all current hepatitis B vaccines. Mechanistically, it acts as an immunogen—stimulating an immune response that leads to antibody production against HBV[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hepatitis b antigen.